Inexia aims to develop intranasally administered orexin positive modulators for the treatment of neurological diseases.The orexin system is a key regulator of behavioural arousal, wakefulness and sleep. The loss of the orexin neurons has been shown to be strongly linked to multiple neurological conditions including narcolepsy. In this indication,orexin receptors remain intact and functional, providing an opportunity for therapeutic intervention.

Biotechnology

Health Care

Neuroscience

Pharmaceutical

Inexia

Inexia's headquarters in London, United Kingdom

Description

People

Jobs